Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Celgene Corp (CELG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 82,526,880
  • Shares Outstanding, K 787,320
  • Annual Sales, $ 11,229 M
  • Annual Income, $ 1,999 M
  • 36-Month Beta 1.77
  • Price/Sales 6.79
  • Price/Cash Flow 17.60
  • Price/Book 8.47

Price Performance

See More
Period Period Low Period High Performance
1-Month
101.13 +2.69%
on 01/08/18
110.20 -5.76%
on 12/18/17
-5.56 (-5.08%)
since 12/15/17
3-Month
94.55 +9.84%
on 10/26/17
139.40 -25.50%
on 10/18/17
-35.01 (-25.21%)
since 10/17/17
52-Week
94.55 +9.84%
on 10/26/17
147.17 -29.44%
on 10/02/17
-11.10 (-9.66%)
since 01/17/17

Most Recent Stories

More News
Is Celgene (CELG) Looking to Take Over Juno Therapeutics?

There are reports that Celgene (CELG) is in talks to acquire Juno Therapeutics to strengthen its portfolio given the recent series of setbacks.

CELG : 103.68 (-1.09%)
BLUE : 174.00 (+6.52%)
GILD : 80.92 (+0.83%)
JUNO : 66.23 (+45.24%)
Biotech Stock Roundup: Juno Surges on Acquisition Rumor, Concert Down on Patent News

Is Celgene (CELG) in talks with Juno regarding a possible acquisition deal? This was the main news in the biotech sector this week.

CELG : 103.68 (-1.09%)
CNCE : 19.13 (-0.57%)
VRTX : 157.35 (+1.05%)
INCY : 90.69 (-1.05%)
GILD : 80.92 (+0.83%)
AMGN : 187.24 (+0.92%)
JUNO : 66.23 (+45.24%)
Concert Pharmaceuticals Plunges on Patent Petition Setback

Shares of Concert Pharmaceuticals (CNCE) nosedive after the Patent Trial and Appeal Board decided not to grant a Post Grant Review petition in patent '335 dispute with Incyte.

CELG : 103.68 (-1.09%)
CNCE : 19.13 (-0.57%)
JAZZ : 150.64 (+0.56%)
VRTX : 157.35 (+1.05%)
4 ETFs Set to Surge in Q4 Earnings

Betting on ETFs with the winning combination of stocks that have a positive Earnings ESP and a favorable Zacks Rank would lead to profits for investors.

CELG : 103.68 (-1.09%)
DHI : 51.14 (+0.61%)
ILMN : 243.43 (+0.83%)
CLR : 56.43 (-0.88%)
BBH : 128.81 (+0.16%)
AMGN : 187.24 (+0.92%)
TOL : 51.19 (+0.71%)
PMR : 39.06 (-0.33%)
LOW : 101.46 (+0.49%)
ITB : 45.26 (+0.64%)
BMRN : 90.01 (-0.25%)
INCY : 90.69 (-1.05%)
HD : 198.04 (+0.88%)
PXE : 23.97 (+0.71%)
EOG : 112.72 (-0.59%)
4 ETFs Set to Surge in Q4 Earnings

Betting on ETFs with the winning combination of stocks that have a positive Earnings ESP and a favorable Zacks Rank would lead to profits for investors.

CELG : 103.68 (-1.09%)
DHI : 51.14 (+0.61%)
ILMN : 243.43 (+0.83%)
CLR : 56.43 (-0.88%)
BBH : 128.81 (+0.16%)
AMGN : 187.24 (+0.92%)
TOL : 51.19 (+0.71%)
PMR : 39.06 (-0.33%)
LOW : 101.46 (+0.49%)
ITB : 45.26 (+0.64%)
BMRN : 90.01 (-0.25%)
INCY : 90.69 (-1.05%)
HD : 198.04 (+0.88%)
PXE : 23.97 (+0.71%)
EOG : 112.72 (-0.59%)
The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex

The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex

CELG : 103.68 (-1.09%)
VRTX : 157.35 (+1.05%)
EXEL : 27.98 (-5.63%)
AMGN : 187.24 (+0.92%)
ALXN : 124.50 (+0.02%)
Can Biotech Keep Last Year's Momentum Alive in 2018?

The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.

CELG : 103.68 (-1.09%)
VRTX : 157.35 (+1.05%)
EXEL : 27.98 (-5.63%)
GILD : 80.92 (+0.83%)
REGN : 374.06 (+1.04%)
AMGN : 187.24 (+0.92%)
ALXN : 124.50 (+0.02%)
Key Takeaways from Pfizer & 3 Other Drug Stocks at Healthcare Conference

Here is a look at key takeaways from presentations made by four major pharma and biotech stocks including Pfizer (PFE) at the annual J.P. Morgan healthcare conference.

CELG : 103.68 (-1.09%)
MRK : 62.22 (+0.24%)
PFE : 36.99 (+1.07%)
BMY : 60.66 (+1.23%)
Big Pharma CEOs Speak About Impact of Tax Reform on M&A

This week, senior executives of some large drug companies discussed the impact of tax reform on mergers and acquisition and their plans to use the excess cash at the JP Morgan HealthCare conference.

CELG : 103.68 (-1.09%)
JNJ : 147.58 (+0.49%)
MRK : 62.22 (+0.24%)
LLY : 85.76 (+0.55%)
AGN : 178.50 (-0.09%)
GILD : 80.92 (+0.83%)
BIIB : 341.31 (+0.73%)
Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus

Focus this week was on preliminary results and 2018 outlooks provided by several companies including Celgene (CELG) at a healthcare conference.

CELG : 103.68 (-1.09%)
VRTX : 157.35 (+1.05%)
AXON : 2.07 (-1.90%)
ABBV : 103.31 (+0.80%)
GILD : 80.92 (+0.83%)
ACOR : 25.00 (-0.20%)
REGN : 374.06 (+1.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical...

See More

Key Turning Points

2nd Resistance Point 108.21
1st Resistance Point 106.51
Last Price 103.71
1st Support Level 103.90
2nd Support Level 102.99

See More

52-Week High 147.17
Fibonacci 61.8% 127.07
Fibonacci 50% 120.86
Fibonacci 38.2% 114.65
Last Price 103.71
52-Week Low 94.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.